Cargando…

Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination

The aggregation of amyloid-β (Aβ) is postulated to be the crucial event in Alzheimer’s disease (AD). In particular, small neurotoxic Aβ oligomers are considered to be responsible for the development and progression of AD. Therefore, elimination of thesis oligomers represents a potential causal thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Antonia Nicole, Ziehm, Tamar, Tusche, Markus, Buitenhuis, Johan, Bartnik, Dirk, Boeddrich, Annett, Wiglenda, Thomas, Wanker, Erich, Funke, Susanne Aileen, Brener, Oleksandr, Gremer, Lothar, Kutzsche, Janine, Willbold, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841555/ https://www.ncbi.nlm.nih.gov/pubmed/27105346 http://dx.doi.org/10.1371/journal.pone.0153035

Ejemplares similares

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
por: van Groen, Thomas, et al.
Publicado: (2017)

Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity
por: Rudolph, Stephan, et al.
Publicado: (2016)

Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity
por: Rudolph, Stephan, et al.
Publicado: (2016)

QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers
por: Brener, Oleksandr, et al.
Publicado: (2015)

In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease
por: Schartmann, Elena, et al.
Publicado: (2018)

Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
por: Elfgen, Anne, et al.
Publicado: (2019)

Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease
por: Jiang, Nan, et al.
Publicado: (2015)

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease
por: Kutzsche, Janine, et al.
Publicado: (2017)

Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy
por: König, Anna S., et al.
Publicado: (2021)

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology
por: Schemmert, Sarah, et al.
Publicado: (2018)

Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo
por: Kass, Bettina, et al.
Publicado: (2022)

Do We Need Anti-Prionic Compounds to Treat Alzheimer’s Disease?
por: Willbold, Dieter, et al.
Publicado: (2019)

The D-amino acid peptide D3 reduces amyloid fibril boosted HIV-1 infectivity
por: Widera, Marek, et al.
Publicado: (2014)

Oral Treatment with d-RD2RD2 Impedes Early Disease Mechanisms in SOD1*G93A Transgenic Mice but Does Not Prolong Survival
por: Wintz, Katharina, et al.
Publicado: (2023)

In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease
por: Schemmert, Sarah, et al.
Publicado: (2021)

Correction: Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination
Publicado: (2016)

Origin of metastable oligomers and their effects on amyloid fibril self-assembly
por: Hasecke, Filip, et al.
Publicado: (2018)

Development of a Small D-Enantiomeric Alzheimer’s Amyloid-β Binding Peptide Ligand for Future In Vivo Imaging Applications
por: Funke, Susanne Aileen, et al.
Publicado: (2012)

A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model
por: Post, Julia, et al.
Publicado: (2021)

Peptides for Therapy and Diagnosis of Alzheimer’s Disease
por: Funke, Susanne Aileen, et al.
Publicado: (2012)

Clustering of human prion protein and α-synuclein oligomers requires the prion protein N-terminus
por: Rösener, Nadine S., et al.
Publicado: (2020)

Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease
por: Funke, Susanne Aileen
Publicado: (2011)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity
por: Stroedicke, Martin, et al.
Publicado: (2015)

Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntington’s Disease Knock-in Mice
por: Schindler, Franziska, et al.
Publicado: (2021)

Met/Val129 polymorphism of the full-length human prion protein dictates distinct pathways of amyloid formation
por: Pauly, Thomas, et al.
Publicado: (2022)

Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay
por: Kühbach, Katja, et al.
Publicado: (2016)

β-Hairpin of Islet Amyloid Polypeptide Bound to an Aggregation Inhibitor
por: Mirecka, Ewa A., et al.
Publicado: (2016)

A near atomic-scale view at the composition of amyloid-beta fibrils by atom probe tomography
por: Rusitzka, Kristiane A. K., et al.
Publicado: (2018)

Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease
por: Dammers, Christina, et al.
Publicado: (2016)

Analysis of the Bin1 SH3 interaction with peptides derived from the hepatitis C virus protein NS5A and c-Myc reveals that NS5A can competitively displace c-Myc in vitro
por: Aladağ, Amine, et al.
Publicado: (2014)

Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth
por: Wördehoff, Michael M., et al.
Publicado: (2017)

Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies
por: Altendorf, Tim, et al.
Publicado: (2023)

Atomic Resolution Insights into pH Shift Induced Deprotonation Events in LS-Shaped Aβ(1–42) Amyloid Fibrils
por: Becker, Nina, et al.
Publicado: (2023)

IQGAP1 Interaction with RHO Family Proteins Revisited: KINETIC AND EQUILIBRIUM EVIDENCE FOR MULTIPLE DISTINCT BINDING SITES
por: Nouri, Kazem, et al.
Publicado: (2016)

Sex-Related Motor Deficits in the Tau-P301L Mouse Model
por: Camargo, Luana Cristina, et al.
Publicado: (2021)

Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease
por: Kutzsche, Janine, et al.
Publicado: (2023)

The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease
por: Albus, Alexandra, et al.
Publicado: (2023)

Immobilization of Homogeneous Monomeric, Oligomeric and Fibrillar Aβ Species for Reliable SPR Measurements
por: Frenzel, Daniel, et al.
Publicado: (2014)

Progress towards structural understanding of infectious sheep PrP-amyloid
por: Müller, Henrik, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jh624lq6eogqg0lg7s19ubg0ac